Skip to main content
Log in

Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease

  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The adenosine A2A receptor antagonist SCH 58261 increases the turning behavior induced by L-dopa in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats. In this study we have evaluated the effect of a chronic intermittent administration of L-dopa or SCH 58261 plus L-dopa on turning behaviour. Chronic intermittent administration of SCH 58261 plus L-dopa produced a stable turning behavior during the course of the treatment, whereas L-dopa alone produced a progressive increase in turning behavior. Moreover, repeated administration of SCH 58261 failed to produce tolerance to its ability to potentiate L-dopa-induced turning behavior. The results indicate that SCH 58261 is effective after chronic administration and suggest that SCH 58261 plus L-dopa, differently from L-dopa alone, does not produce alterations in motor responses during the course of the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morelli, M., Pinna, A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 22, 71–72 (2001). https://doi.org/10.1007/s100720170052

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s100720170052

Keywords

Navigation